1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- AstraZeneca
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- MORE
Patients with hypertension are generally treated with drugs that can reduce blood volume (reducing central venous pressure and cardiac output), reduce systemic vascular resistance, and reduce cardiac output by depressing heart rate and stroke volume. For instance, diuretic drugs decrease the blood volume by increasing urine output by the kidney. Similarly, vasodilator drugs dilate blood vessels through the relaxation of smooth muscle in blood vessels.
Cardioinhibitory drugs depress cardiac function by decreasing heart rate, myocardial contractility, or both, which decreases cardiac output and arterial pressure. Hence, the availability of a wide range of therapeutics is offering specific treatment to the patients with hypertension and driving the growth of the global antihypertensive drugs market during the forecast period. The analysts have predicted that the antihypertensive drugs market will register a CAGR of over 2% by 2023.
Market Overview
Rising population with risk factors of hypertension
Some medical conditions can raise the risk of high blood pressure. The growing prevalence of diabetes increases the risk of development of hypertension. Hence, an increase in the number of people with these risk factors is expected to increase the number of people with hypertension. This, in turn, is expected to aid in the use of available drugs, which will drive the growth of the global antihypertensive drugs market during the forecast period.
Increasing generics popularity
Generic medicines contain the same active ingredient in the same quantity as a branded medicine. The development of generic drugs is simple and less time-taking. Therefore, the launch of generic drugs with lesser price than the innovator drugs is diluting and deceleration the market growth and is expected to hamper the growth of the market during our forecast period.
For the detailed list of factors that will drive and challenge the growth of the antihypertensive drugs market during the 2019-2023, view the full report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Cardioinhibitory drugs depress cardiac function by decreasing heart rate, myocardial contractility, or both, which decreases cardiac output and arterial pressure. Hence, the availability of a wide range of therapeutics is offering specific treatment to the patients with hypertension and driving the growth of the global antihypertensive drugs market during the forecast period. The analysts have predicted that the antihypertensive drugs market will register a CAGR of over 2% by 2023.
Market Overview
Rising population with risk factors of hypertension
Some medical conditions can raise the risk of high blood pressure. The growing prevalence of diabetes increases the risk of development of hypertension. Hence, an increase in the number of people with these risk factors is expected to increase the number of people with hypertension. This, in turn, is expected to aid in the use of available drugs, which will drive the growth of the global antihypertensive drugs market during the forecast period.
Increasing generics popularity
Generic medicines contain the same active ingredient in the same quantity as a branded medicine. The development of generic drugs is simple and less time-taking. Therefore, the launch of generic drugs with lesser price than the innovator drugs is diluting and deceleration the market growth and is expected to hamper the growth of the market during our forecast period.
For the detailed list of factors that will drive and challenge the growth of the antihypertensive drugs market during the 2019-2023, view the full report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- AstraZeneca
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global antihypertensive drugs market pipeline: Overview
Exhibit 18: Phase III pipeline molecules: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Systemic hypertension - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Systemic hypertension - Year-over-year growth 2019-2023 (%)
Exhibit 23: Pulmonary hypertension - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the drugs available for treatment of pulmonary hypertension
Exhibit 25: Pulmonary hypertension - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Available drugs for treatment of hypertension: Overview
Exhibit 45: Generic drugs that received approval from US FDA for treatment of hypertension since 2016: Overview
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca - Vendor overview
Exhibit 53: AstraZeneca - Business segments
Exhibit 54: AstraZeneca - Organizational developments
Exhibit 55: AstraZeneca - Geographic focus
Exhibit 56: AstraZeneca - Key offerings
Exhibit 57: AstraZeneca - Key customers
Exhibit 58: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 59: Johnson & Johnson Services, Inc. - Business segments
Exhibit 60: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 61: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 62: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 63: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 64: Johnson & Johnson Services, Inc. - Key customers
Exhibit 65: Merck & Co., Inc. - Vendor overview
Exhibit 66: Merck & Co., Inc. - Business segments
Exhibit 67: Merck & Co., Inc. - Organizational developments
Exhibit 68: Merck & Co., Inc. - Geographic focus
Exhibit 69: Merck & Co., Inc. - Segment focus
Exhibit 70: Merck & Co., Inc. - Key offerings
Exhibit 71: Merck & Co., Inc. - Key customers
Exhibit 72: Novartis AG - Vendor overview
Exhibit 73: Novartis AG - Business segments
Exhibit 74: Novartis AG - Organizational developments
Exhibit 75: Novartis AG - Geographic focus
Exhibit 76: Novartis AG - Segment focus
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Novartis AG - Key customers
Exhibit 79: Pfizer Inc. - Vendor overview
Exhibit 80: Pfizer Inc. - Business segments
Exhibit 81: Pfizer Inc. - Organizational developments
Exhibit 82: Pfizer Inc. - Geographic focus
Exhibit 83: Pfizer Inc. - Segment focus
Exhibit 84: Pfizer Inc. - Key offerings
Exhibit 85: Pfizer Inc. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: List of abbreviations
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Systemic hypertension - Market size and forecast 2018-2023
- Pulmonary hypertension - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Research methodology
- List of abbreviations
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global antihypertensive drugs market pipeline: Overview
Exhibit 18: Phase III pipeline molecules: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Systemic hypertension - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Systemic hypertension - Year-over-year growth 2019-2023 (%)
Exhibit 23: Pulmonary hypertension - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the drugs available for treatment of pulmonary hypertension
Exhibit 25: Pulmonary hypertension - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Available drugs for treatment of hypertension: Overview
Exhibit 45: Generic drugs that received approval from US FDA for treatment of hypertension since 2016: Overview
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AstraZeneca - Vendor overview
Exhibit 53: AstraZeneca - Business segments
Exhibit 54: AstraZeneca - Organizational developments
Exhibit 55: AstraZeneca - Geographic focus
Exhibit 56: AstraZeneca - Key offerings
Exhibit 57: AstraZeneca - Key customers
Exhibit 58: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 59: Johnson & Johnson Services, Inc. - Business segments
Exhibit 60: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 61: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 62: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 63: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 64: Johnson & Johnson Services, Inc. - Key customers
Exhibit 65: Merck & Co., Inc. - Vendor overview
Exhibit 66: Merck & Co., Inc. - Business segments
Exhibit 67: Merck & Co., Inc. - Organizational developments
Exhibit 68: Merck & Co., Inc. - Geographic focus
Exhibit 69: Merck & Co., Inc. - Segment focus
Exhibit 70: Merck & Co., Inc. - Key offerings
Exhibit 71: Merck & Co., Inc. - Key customers
Exhibit 72: Novartis AG - Vendor overview
Exhibit 73: Novartis AG - Business segments
Exhibit 74: Novartis AG - Organizational developments
Exhibit 75: Novartis AG - Geographic focus
Exhibit 76: Novartis AG - Segment focus
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Novartis AG - Key customers
Exhibit 79: Pfizer Inc. - Vendor overview
Exhibit 80: Pfizer Inc. - Business segments
Exhibit 81: Pfizer Inc. - Organizational developments
Exhibit 82: Pfizer Inc. - Geographic focus
Exhibit 83: Pfizer Inc. - Segment focus
Exhibit 84: Pfizer Inc. - Key offerings
Exhibit 85: Pfizer Inc. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4
FEATURED COMPANIES
- AstraZeneca
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- MORE
Global Antihypertensive Drugs Market 2019-2023
The analyst recognizes the following companies as the key players in the global antihypertensive drugs market: AstraZeneca, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc..
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of modified release formulations.”
According to the report, one of the major drivers for this market is the increases funds for the research on hypertension.
Further, the report states that one of the major factors hindering the growth of this market is the drug failures in late- stage clinical trials.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global antihypertensive drugs market: AstraZeneca, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc..
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of modified release formulations.”
According to the report, one of the major drivers for this market is the increases funds for the research on hypertension.
Further, the report states that one of the major factors hindering the growth of this market is the drug failures in late- stage clinical trials.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 4
- AstraZeneca
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
